IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Julia Hofmann, Head of Public and Investor Relations
Tel.: +49 89 200033-3301
E-Mail: investor@medigene.com

FRüHERE MELDUNGEN

pta20181112031
Public disclosure of inside information according to article 17 MAR

Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor


Martinsried/Munich (pta031/12.11.2018/18:50) - Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced that it has entered into an exclusive license agreement with Leiden University Medical Center (LUMC), the Netherlands, for worldwide rights to develop, manufacture, and commercialize an HA-1-specific T cell receptor (TCR) as a targeted immunotherapy for cancer.

The TCR specific for the minor histocompatibility antigen HA-1 was developed by LUMC and tested for preliminary safety and tolerability in a Phase I clinical trial involving five patients. HA-1 is a well-characterized antigen expressed in cells of the hematopoietic system, in leukemia and lymphoma cells, as well as expressed in various solid tumors.

Medigene has licensed this HA-1-targeting T cell receptor to complement Medigene's preclinical and clinical development program. Its potential applicability in both liquid and solid tumors makes strategic sense within Medigene's growing internal pipeline.

Under the terms of the agreement, Medigene will receive the exclusive worldwide development and commercialization rights to the HA-1-specific TCR developed by LUMC. In return, LUMC will receive a one-time payment along with certain milestone payments. Upon commercialization, LUMC is eligible for royalties in the low-single digit percentage range. Confidentiality was agreed regarding further financial details.

Terms of the deal do not materially impact Medigene's financial guidance for the balance of the year 2018.

Contact Medigene
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

Should you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg
Germany
contact person: Julia Hofmann, Head of Public and Investor Relations
phone: +49 89 200033-3301
e-mail: investor@medigene.com
website: www.medigene.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
|
|
98.402 Abonnenten
|
181.916 Meldungen
|
74.314 Pressefotos

BUSINESS

05.08.2020 - 13:50 | results & relations Gesellschaft für Kommunikation GmbH
05.08.2020 - 12:05 | Vogel Communications Group GmbH & Co. KG
05.08.2020 - 11:00 | G DATA CyberDefense AG
05.08.2020 - 10:30 | pressetext.redaktion
05.08.2020 - 09:20 | IG Windkraft
Top